While the fight against COVID-19 is not in the distant past, it has been already overshadowed by a range of macroeconomic and geopolitical factors. At the same time, ongoing drug pricing and reimbursement constraints, regulatory pressures, and biotech funding instability will continue to test pharmaceutical industry in the coming years. In this “Thematic Intelligence: The State of the Biopharmaceutical Industry 2024 Edition” report, the Publisher examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2024.
- Post-COVID-19 recovery is met by a range of macroeconomic and geopolitical challenges.
- Genomics, IO drug development, personalized/precision medicine and CGTs will dominate as the most impactful trends in the biopharmaceutical industry in 2024.
- Among the most impactful trends, cell and gene therapies will be the key focus in 2024.
- Geopolitical conflicts, inflation, and drug pricing pressures will be the top hindrances for pharmaceutical sector growth.
- Vertical integration, patent expiry of biologics, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry.
- Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2024.
- Across pharma value chain components, drug development and end users experience are lagging behind with innovation adoption.
- The biopharmaceutical industry is more optimistic about industry growth in the next 12 months as compared to 2023, but level of optimism is still below 2022 levels.
- A total of 44% of survey respondents expressed an optimistic or very optimistic sentiment on the biotech funding recovery in 2024.
- Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023.
- Oncology remains the single largest therapy area going into 2024, but metabolic disorders display the highest growth.
- The IRA is believed to open the door to government price negotiation across all pharmaceuticals.
Key Highlights
- There is hope for more stability in 2024, but the road is still rocky.
- CGT is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2024.
- Inflation, geopolitical conflicts, and drug pricing and reimbursement-related concerns will be the leading impediment to industry growth.
- Vertical integration, patent expiry of biologics, and ESG factors will have the most positive impacts on industry.
- AI is set to bring disruptive change in pharmaceutical industry
- Optimism about the pharmaceutical sector’s growth prospects recovered from the lows seen in 2023.
Scope
- Benchmark the impact of major themes on the biopharmaceutical industry in 2024, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.
- Identify themes that will have the greatest positive or negative impact in 2024.
- Capture opinions on these themes from industry respondents.
- Predict the industry’s growth prospects in 2024.
Reasons to Buy
- Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2024.
- Explore how the biopharmaceutical landscape has changed.
- Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2024.
- Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry.
- Identify emerging industry trends and innovations to gain a competitive advantage.
Table of Contents
1. Executive Summary2. Study Design
3. Emerging Industry Trends
4. Emerging Regulatory and Macroeconomic Trends
5. Emerging Technologies
6. Industry’s Growth Prospects
7. Watch Outs
8. Summary of Key Findings
9. Appendix
10. Authors and Contributors
11. Thematic Research Methodology
12. Contact the Publisher
List of Tables
- Table 1: First-in-class personalized medicine drugs launching in 2024 for oncology indications
- Table 2a: Use of digital/connected devices among patients
- Table 2b: Agreement level with digital/connected devices ability to improve health management
- Table 3: Percentage of patients who agreed or strongly agreed with different statements
- Table 4: AI can be used across the entire pharma value chain
- Table 5: Inflation Reduction Act
- Table 6: Products selected for Medicare price negotiation
- Table 7: Drug Launches - 2024
- Table 8: Abbreviations
- Table 9: Abbreviations
- Table 10: Related reports
- Figure 1: Respondent Mix - Geography
- Figure 2a: Respondent Mix - Seniority Level
- Figure 2b: Respondent Mix - Company size
- Figure 3: Respondent Mix - Headquarter locations
- Figure 4: Top emerging pharmaceutical industry trend for 2024
- Figure 5: The importance of industry trends: 2023 versus 2024
- Figure 6: The most impactful industry trends by region
- Figure 7: The most impactful industry trends by region
- Figure 8: Trend having the greatest impact on the pharmaceutical industry in 2024
- Figure 9: CGT Market Value by Indication 2022-2029
- Figure 10: Number of RWE Trials by Sponsor Type and Year
- Figure 11a: mRNA Vaccines in Oncology by Trial Phases
- Figure 11b: mRNA Vaccines in Oncology - Company vs Instituion
- Figure 12a: mRNA Vaccines for Infectious Diseases by Trial Phases
- Figure 12b: mRNA Vaccines for Infectious Diseases - Company vs Instituion
- Figure 13a: Development of ICIs
- Figure 13b: Development of CART-T Therapies
- Figure 14: International Reference Pricing Policy Changes Influenced by Drug Shortages
- Figure 15: DTx in Europe - Number of Products Reimbursed per Market
- Figure 16a: Microbiome Agents in Development in Different Therapy Areas
- Figure 16b: Percentage of Microbiome Agents in Development for Different Indications in Infectious Diseases
- Figure 16c: Percentage of Microbiome Agents in Development for Different Gastrointestinal Indications
- Figure 16d: Number of Clinical Trials Initiated per Year with Microbiome-Targeting Therapeutics
- Figure 17: Most Commonly Used Component in DCTs
- Figure 18: Percentage of Clinical Trials Using Decentralized/Virtual Clinical Trial Components
- Figure 19: Emerging Regulatory and Macroeconomic Trends Expected to Have Positive and Negative Impact on Pharmaceutical Industry in 2024
- Figure 20: Emerging Regulatory and Macroeconomic Trends - High Positive Score vs Low Negative Score
- Figure 21: Pharmaceutical Price Trends, 2018-2022
- Figure 22: Number of 2023 Risk Events with a Positive or Negative Impact on Market Access
- Figure 23a: Annual Company Reports with Inflation Mentions
- Figure 23b: Annual Company Reports with Recession Mentions
- Figure 24: Geopolitical Conflicts Expected to bring Negative Impact on Pharmaceutical Industry in 2024
- Figure 25a: Crohn's Disease: Biosimilar Sales Forcast, 8MM, 2022-2032
- Figure 25b: Crohn's Disease: Average Biosimilar Prescription, 8MM, 2022-2032
- Figure 26: Number of New COVID-19 Clinical Trials by Year
- Figure 27: Emerging Regulatory and Macroeconomic Trends - Greatest Positive Score vs Greatest Negative Score
- Figure 28: Top Positive Emerging Regulatory and Macroeconomic trends by Geography
- Figure 29: Emerging Regulatory and Macroeconomic Trends - High Positive Scores vs Low Negative Scores, 2022 vs 2023
- Figure 30: Anticipated Impact of Emerging Technologies on the Pharmaceutical Industry in 2024
- Figure 31: Top 5 Most Impactful Emerging Technologies 2020-2024
- Figure 32: Value Chain Components Lagging Behind the Most with the Adoption of Innovations
- Figure 33: Increase in Investment in Emerging Technologies Due to Inflation
- Figure 34: Decrease in Investment in Emerging Technologies Due to Inflation
- Figure 35: Emerging Technologies Expected to Have the Greatest Impact on the Pharmaceutical Industry in 2024
- Figure 36: Top 6 Emerging Technologies Expected to Have the Greatest Impact on the Pharmaceutical Industry 2020-2024
- Figure 37a: Optimism on Industry's Growth during the Next 12 Months
- Figure 37b: Optimism on Industry's Growth during the Next 12 Months, by Geography
- Figure 38: Optimism on Industry's Growth during the Next 12 Months, 2020-2024
- Figure 39a: Most Disruptive Technologies in the Next Two Years
- Figure 39b: Most Disruptive Technologies in the Next Two Years, 2019-2022
- Figure 40a-h: Top Technologies Best Positioned to Improve Processes within Pharmaceutical Value Chain
- Figure 41a: the analyst's US Market Outlook in Obesity: GLP-1 RA Class, 2021
- Figure 41b: the analyst's US Market Outlook in Obesity: GLP-1 RA Class, 2031
- Figure 42: IRA’s Impact on the Biopharmaceutical Industry
- Figure 43a: Optimism regarding the biotech funding recovery in the next 12 months
- Figure 43b: Optimism regarding the biotech funding recovery in the next 12 months, by geography
- Figure 44a: Support measures to tackle the downturn in biotech funding
- Figure 44b: Support measures to tackle the downturn in biotech funding, by geography
- Figure 45: Private Biotech Venture Financing, 2013-2023
- Figure 46a: Small business innovation grant funding
- Figure 46b: NIH grant funding to academia
- Figure 47a: Planned clinical trials in 2023 by phase
- Figure 47b: Top industry sponsors for planned clinical trials in 2024
- Figure 48a: Top countries for planned clinical trials in 2024 by number and phase
- Figure 48b: Drug types for planned clinical trials in 2024 by phase
- Figure 49a: Top therapy areas for planned clinical trials to be initiated in 2024
- Figure 49b: Top indications for planned clinical trials to be initiated in 2024
- Figure 50a: Projected trial completion in 2023 by phase
- Figure 50b: Top industry sponsors for trials projected to be completed in 2024
- Figure 51: Top 10 prescription drugs, 2023 vs 2024
- Figure 52: Top 10 therapy areas, 2023 vs 2024
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Absci
- Actinium Pharmaceutical
- Adaptimmune
- Aetna
- Altaris Capital Partners
- Alvotech
- Amgen
- Aqemia
- Astellas Pharma
- AstraZeneca
- Bayer
- BenevolentAI
- Berkshire Sterile Manufacturing (BSM)
- Biocon Biologics
- Biogen
- BioNTech
- Biosynth
- Bio-Thera Solutions
- Boehringer Ingelheim
- BridgeBio Pharma
- Bristol Myers Squibb
- Catalent
- Celares Gmbh
- Celltrion
- Cigna’s
- CVS Health
- Day One Biopharmaceutical
- Dr Reddy's lab
- Eli Lilly
- Exelead
- Express Scripts
- Exscientia
- Ferring Pharma
- Formycon
- Fresenius Kabi
- Fuji Pharma
- Genmab
- Geron Corp
- IASO Bio
- ImmunityBio
- Incyte
- Insilico
- Insud Pharma
- Johnson & Johnson
- Junshi Bio
- Juventas
- Karuna Therapeutics
- Lonza
- mAbxience
- Madrigal Pharmaceuticals Inc
- Merck & Co
- Metrics Contract Services
- Mochida Pharmaceutical
- Moderna
- Mylan
- Novartis
- Novo Nordisk
- Optum
- Amedisys
- Pear Therapeutics
- Pfizer
- Regeneron
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Seres Therapeutics
- Sharp Services Inc
- STgen Bio
- Strides Pharma Science
- Synaffix
- Syndax Pharmaceutical
- Teladoc Health
- TheraPlatform
- Tricida
- UnitedHealth
- Veranova
- Verona Pharma Plc
- Viatris
- Zhaoke Ophthalmology
